GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » BioDelivery Sciences International Inc (NAS:BDSI) » Definitions » ROC (Joel Greenblatt) %

BioDelivery Sciences International (BioDelivery Sciences International) ROC (Joel Greenblatt) % : 275.93% (As of Dec. 2021)


View and export this data going back to 2002. Start your Free Trial

What is BioDelivery Sciences International ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. BioDelivery Sciences International's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2021 was 275.93%.

The historical rank and industry rank for BioDelivery Sciences International's ROC (Joel Greenblatt) % or its related term are showing as below:

BDSI' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1928.35   Med: -340.51   Max: 309.65
Current: 225.49

During the past 13 years, BioDelivery Sciences International's highest ROC (Joel Greenblatt) % was 309.65%. The lowest was -1928.35%. And the median was -340.51%.

BDSI's ROC (Joel Greenblatt) % is not ranked
in the Drug Manufacturers industry.
Industry Median: 7.85 vs BDSI: 225.49

BioDelivery Sciences International's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


BioDelivery Sciences International ROC (Joel Greenblatt) % Historical Data

The historical data trend for BioDelivery Sciences International's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioDelivery Sciences International ROC (Joel Greenblatt) % Chart

BioDelivery Sciences International Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -52.70 -628.31 128.32 309.65 239.80

BioDelivery Sciences International Quarterly Data
Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 278.33 165.39 246.93 214.11 275.93

Competitive Comparison of BioDelivery Sciences International's ROC (Joel Greenblatt) %

For the Drug Manufacturers - Specialty & Generic subindustry, BioDelivery Sciences International's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioDelivery Sciences International's ROC (Joel Greenblatt) % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioDelivery Sciences International's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where BioDelivery Sciences International's ROC (Joel Greenblatt) % falls into.



BioDelivery Sciences International ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Sep. 2021 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(57.572 + 23.075 + 6.904) - (67.748 + 0 + 6.832)
=12.971

Working Capital(Q: Dec. 2021 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(56.867 + 23.711 + 7.178) - (71.666 + 0 + 6.097)
=9.993

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of BioDelivery Sciences International for the quarter that ended in Dec. 2021 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2021 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2021  Q: Dec. 2021
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=36.188/( ( (1.525 + max(12.971, 0)) + (1.741 + max(9.993, 0)) )/ 2 )
=36.188/( ( 14.496 + 11.734 )/ 2 )
=36.188/13.115
=275.93 %

Note: The EBIT data used here is four times the quarterly (Dec. 2021) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioDelivery Sciences International  (NAS:BDSI) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


BioDelivery Sciences International ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of BioDelivery Sciences International's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


BioDelivery Sciences International (BioDelivery Sciences International) Business Description

Traded in Other Exchanges
N/A
Address
4131 ParkLake Avenue, Suite 225, Raleigh, NC, USA, 27612
BioDelivery Sciences International Inc is a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic pain. The company is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of therapies aimed at addressing important unmet medical needs. Its products include Belbuca and Symproic.
Executives
James Vollins officer: See Remarks C/O BIODELIVERY SCIENCES INTERNATIONAL, 4131 PARK LAKE AVE SUITE 225, RALEIGH NC 27607
Mark A Sirgo director C/O BIODELIVERY SCIENCES INTERNATIONAL, 801 CORPORATE CENTER DRIVE -SUITE 210, RALEIGH NC 27607
Broadfin Healthcare Master Fund Ltd director C/O 20 GENESIS CLOSE, ANSBACHER HOUSE, 2ND FLOOR, PO BOX 1344, GRAND CAYMAN E9 KY1-1108
Kevin Kotler director C/O BROADFIN CAPITAL, LLC, 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Mary Theresa Coelho officer: See Remarks 52 SUNRISE PARK ROAD, NEW HAMPTON NY 43017
Jeffrey Allen Bailey director, officer: Chief Executive Officer BIODELIVERY SCIENCES INTERNATIONAL, INC., 4131 PARKLAKE AVE., SUITE 225, RALEIGH NC 27612
Todd C Davis director 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
W. Mark Watson director 324 S. HYDE PARK AVENUE, STE 350, TAMPA FL 33606
Peter Greenleaf director ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Broadfin Capital, Llc director 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Vanila Singh director C/O BIODELIVERY SCIENCES INTERNATIONAL, 4131 PARKLAKE AVE., SUITE 225, RALEIGH NC 27612
Scott M. Plesha officer: See Remarks 1410 SMYTHE ST DANIEL ISLAND SC 29492
Odonnell Francis E Jr director BIODELIVERY SCIENCES INTERNATIONAL, INC, 4131 PARKLAKE AVENUE, SUITE #225, RALEIGH NC 27612
Herm Cukier director, officer: Chief Executive Officer C/O BIODELIVERY SCIENTES INT., INC. 4131 PARKLAKE AVE, SUITE 225 RALEIGH NC 27612
Thomas B Smith officer: Chief Medical Officer BIODELIVERY SCIENCES INTERNATIONAL, INC., 4131 PARKLAKE AVE SUITE 225, RALEIGH NC 27612

BioDelivery Sciences International (BioDelivery Sciences International) Headlines

From GuruFocus

Collegium to Acquire BioDelivery Sciences in an All-Cash Deal

By GuruFocusNews GuruFocusNews 02-14-2022

BioDelivery Sciences International to Host ELYXYB� Investor Day

By Marketwired Marketwired 09-30-2021